0000950170-23-045176.txt : 20230830 0000950170-23-045176.hdr.sgml : 20230830 20230830071419 ACCESSION NUMBER: 0000950170-23-045176 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230829 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230830 DATE AS OF CHANGE: 20230830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981007018 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 231223683 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 8-K 1 alks-20230829.htm 8-K 8-K
0001520262FalseAlkermes plc.00015202622023-08-292023-08-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 29, 2023

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

Ireland

 

001-35299

 

98-1007018

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

 

 

 

 

Connaught House, 1 Burlington Road

Dublin 4, Ireland D04 C5Y6

(Address of principal executive offices)

 

Registrant's telephone number, including area code: + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

☐

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary shares, $0.01 par value

 

ALKS

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On August 29, 2023, Alkermes, Inc. and Alkermes Pharma Ireland Limited, subsidiaries of Alkermes plc (together, “Alkermes”), entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Teva Pharmaceuticals USA, Inc. (“Teva”, and together with Alkermes, the “parties”) relating to Alkermes’ product VIVITROL® (naltrexone for extended-release injectable suspension). The Settlement Agreement resolves patent litigation brought by Alkermes against Teva related to the infringement of Orange Book-listed United States Patent No. 7,919,499 with respect to Teva’s Abbreviated New Drug Application (“ANDA”) No. 213195. Pursuant to the terms of the Settlement Agreement, Alkermes will grant Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license to make, have made, use, import, sell and offer for sale Teva’s product made under ANDA No. 213195 in the United States beginning on January 15, 2027, or earlier under certain circumstances.

 

The Settlement Agreement obligates the parties to promptly file a joint Stipulated Consent Judgment and Injunction to dismiss pending legal proceedings. The Settlement Agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. The description of the Settlement Agreement contained herein does not purport to be complete and is qualified in its entirety by reference to the Settlement Agreement, which Alkermes intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2023.

 

Item 7.01 Regulation FD Disclosure.

 

On August 30, 2023, Alkermes issued a press release announcing the Settlement Agreement, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This Item 7.01 and Exhibit 99.1 furnished herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release issued by Alkermes plc dated August 30, 2023.

104

 

Cover page interactive data file (embedded within the Inline XBRL document).

 

2

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ALKERMES PLC

 

 

Date: August 30, 2023

By:

 

/s/ David J. Gaffin

 

 

 

David J. Gaffin

 

 

 

Secretary

 

3

 EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

 

Alkermes Contacts:

For Investors: Sandy Coombs +1 781 609 6377

For Media: Marisa Borgasano +1 781 609 6659

 

 

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

 

—
Company Grants Teva a License to Market Generic VIVITROL Beginning in January 2027 —

 

DUBLIN, August 30, 2023 -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. (“Teva”) to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension). Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No. 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.

Additional details regarding the settlement agreement were not disclosed. The company and Teva will submit the settlement agreement for review to the United States Federal Trade Commission and the United States Department of Justice.

This patent litigation was initiated by the company in September 2020 in response to Teva’s abbreviated new drug application seeking United States Food and Drug Administration approval of a generic version of VIVITROL in the United States prior to the expiration of Alkermes’ U.S. Patent No. 7,919,499, an Orange Book-listed patent for VIVITROL that expires in 2029. The parties completed a trial in March 2023. In connection with the settlement, the company and Teva will file a proposed Stipulated Consent Judgment and Injunction with the U.S. District Court for the District of New Jersey requesting that the Court dismiss the pending litigation between the parties.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

 

 

 

Note Regarding Forward-Looking Statements


Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the terms of the settlement agreement with Teva, expectations regarding the impact of the settlement agreement and submission of the settlement agreement for review to the United States Federal Trade Commission and the United States Department of Justice. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties, including the unfavorable outcome of other litigation, including so-called “Paragraph IV” litigation and other patent litigation, related to VIVITROL, which may lead to competition from generic drug manufacturers; the outcome of any review of the settlement agreement by the United States Federal Trade Commission and United States Department of Justice; and those risks and uncertainties described under the heading “Risk Factors” in the company’s most recent Annual Report on Form 10-K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

 

VIVITROL® is a registered trademark of Alkermes, Inc.

###

 

 EX-101.LAB 3 alks-20230829_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Entity Address, Country Entity Address, Country Document Type Document Type EX-101.PRE 4 alks-20230829_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 5 alks-20230829.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 29, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 29, 2023
Entity Registrant Name Alkermes plc.
Entity Central Index Key 0001520262
Entity Emerging Growth Company false
Entity File Number 001-35299
Entity Incorporation, State or Country Code L2
Entity Tax Identification Number 98-1007018
Entity Address, Address Line One Connaught House
Entity Address, Address Line Two 1 Burlington Road
Entity Address, City or Town Dublin 4
Entity Address, Country IE
Entity Address, Postal Zip Code D04 C5Y6
City Area Code 353
Local Phone Number 1-772-8000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary shares, $0.01 par value
Trading Symbol ALKS
Security Exchange Name NASDAQ
XML 7 alks-20230829_htm.xml IDEA: XBRL DOCUMENT 0001520262 2023-08-29 2023-08-29 0001520262 false Alkermes plc. 8-K 2023-08-29 L2 001-35299 98-1007018 Connaught House 1 Burlington Road Dublin 4 IE D04 C5Y6 353 1-772-8000 false false false false Ordinary shares, $0.01 par value ALKS NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports alks-20230829.htm alks-20230829.xsd alks-20230829_lab.xml alks-20230829_pre.xml alks-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alks-20230829.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "alks-20230829.htm" ] }, "labelLink": { "local": [ "alks-20230829_lab.xml" ] }, "presentationLink": { "local": [ "alks-20230829_pre.xml" ] }, "schema": { "local": [ "alks-20230829.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alks", "nsuri": "http://www.alkermes.com/20230829", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alks-20230829.htm", "contextRef": "C_e590bf84-d4f3-4cba-90ff-a9e73693f0d1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "alks-20230829.htm", "contextRef": "C_e590bf84-d4f3-4cba-90ff-a9e73693f0d1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "verboseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "verboseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.alkermes.com/20230829/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-045176-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-045176-xbrl.zip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